Novartis retreats from TIGIT, handing $300M candidate back to BeiGene

Novartis may have insisted earlier this year that it hadn’t given up on anti-TIGIT checkpoint inhibitors, but, now, the Swiss Big Pharma seems to have had a change of heart. Having paid $300 million to enter the TIGIT space by acquiring ociperlimab in 2021, Novartis is now handing the candidate back to BeiGene.